



PEER-REVIEW REPORT

Name of journal: *World Journal of Nephrology*

Manuscript NO: 98393

Title: Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: a retrospective study

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 08170404

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Poland

Author's Country/Territory: Russia

Manuscript submission date: 2024-06-25

Reviewer chosen by: Yu-Fei Wei

Reviewer accepted review: 2024-07-19 10:44

Reviewer performed review: 2024-07-27 20:54

Review time: 8 Days and 10 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The study describes the use of rituximab in juvenile systemic lupus erythematosus in ERA and LRA protocols, comparing their efficacy and clinical benefits for patients. Dear Authors, Thank you very much for the opportunity to read such an interesting article. I think it represents a really good level. The following are my suggestions for its improvement: Title: In the title of the paper, I would add what type of scientific research it is, to provide greater clarification for potential readers. 1. Please use one abbreviation for juvenile systemic lupus erythematosus. Once time you use SLE and once other time you use jSLE. 2. I recommend linguistic review of the article, especially for style in some sentences. 3. Please indicate in the “Methods” section at what time interval subjects were recruited. If possible, I would ask to know what percentage of the total number of patients of the Center were the subjects of the study. This would be very useful information, outlining the scale of the whole problem. 4. I would recommend marking in tables the statistically significant results, for example, by adding the * symbol next to a statistically significant p-value or highlighting in a different color/bold. In addition, after applying the above changes, please place an appropriate annotation in the legend



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

below the tables. 5. In the Results section, please explain the exact meaning of the numbers in parentheses, whether it is IQR, median, or SD, for example (IQR: 0;9). 6. In the "Patients' characteristics on the onset" section, please put the data with percentages in the overhangs together with the p-value. This will make the text more readable and obvious to readers. 7. Please re-evaluate your manuscript for abbreviations. If you introduce an abbreviation with an explanation then please provide it consistently throughout the rest of the manuscript. If you are using it for the first time, please explain it thoroughly the first time you use it. 8. Please add more recent papers in the references if possible. Less than half of them are from the last 5 years, I recommend searching for more recent literature. If this is not possible, due to the nature of the topic, please provide this information in your response to the Editor. 9. Please improve the description of Figure 3 to make it more readable. For example:(left part), (right part) or left part:..., right part:.... . 10. I think that adding a short section comparing the treatment of jSLE and SLE to the introduction section or discussion section would be really valuable, especially for clinicians who are not rheumatologists but are interested in the topic of the article. The above tips are only suggestions that will help improve the manuscript to make it more readable and accessible. I have no comments on the methodology, study design, or its implementation. I greatly appreciate the addition of the study limits, in this section I have nothing to add. The authors also noted how the described limits can be resolved, as a guide for future studies. Ethics and financing have been properly described. My recommendation is to accept the article after major corrections.